857071-75-1

Basic information

• Product Name: (E)-3-(4-Methyl-2-nitrophenyl)prop-2-en-1-ol
• Synonyms: (E)-3-(4-Methyl-2-nitrophenyl)prop-2-en-1-ol;(E)-3-(4-Methyl-2-nitrophenyl)prop-2-en-1-ol-3
• CAS NO: 857071-75-1
• Molecular Formula: C10H11NO3
• Molecular Weight: 193.19924
• Mol File: 857071-75-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-3-(4-Methyl-2-nitrophenyl)prop-2-en-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(4-Methyl-2-nitrophenyl)prop-2-en-1-ol(857071-75-1)
• EPA Substance Registry System: (E)-3-(4-Methyl-2-nitrophenyl)prop-2-en-1-ol(857071-75-1)

Safety Data

• Hazardous Substances Data: 857071-75-1(Hazardous Substances Data)

Usage

Uses

Used in Fragrance and Flavor Industry:
(E)-3-(4-Methyl-2-nitrophenyl)prop-2-en-1-ol is used as a key component in the production of fragrances and flavors due to its distinctive aromatic properties. Its ability to impart pleasant scents makes it a valuable addition to the creation of perfumes, colognes, and a range of flavored products.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, (E)-3-(4-Methyl-2-nitrophenyl)prop-2-en-1-ol serves as an essential intermediate in the synthesis of various medicinal compounds. Its chemical structure allows for its use in developing new drugs and enhancing the effectiveness of existing ones.
It is crucial to handle (E)-3-(4-Methyl-2-nitrophenyl)prop-2-en-1-ol with care, as it can pose health risks if ingested or inhaled in large amounts, highlighting the importance of safety measures during its production and use.

Upstream product

• 105910-05-2 3-(4-methyl-2-nitrophenyl)acrylic acid ethyl ester 

Relevant articles and documents

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)

A preceding paper (Bonfanti et al. J. Med Chem. 2007, 50, 4572-4584) reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-RSV activity. This paper describes a molecular modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clinical candidate.

AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION

Aminobenzimidazoles and benzimidazoles having inhibitory activity on RSV replication and having the formula (I) the prodrugs, N-oxides, addition salts, quaternary amines, metal complexes and stereochemically isomeric forms thereof; wherein G is a direct b